Autres langues Laekna, Inc.

Actions

2105

KYG5340S1093

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:39 28/05/2024			Varia. 5j.	Varia. 1 janv.
7,04 ^HKD	+0,14%		-9,16%	-64,62%

23/05	La FDA américaine donne son feu vert à l'essai clinique de phase 3 de Laekna pour un médicament contre le cancer de la prostate ; les actions augmentent de 8%.	MT
23/05	Laekna, Inc. annonce l'approbation par la Food and Drug Administration américaine du protocole de l'essai clinique de phase III de LAE002 (Afuresertib) plus LAE001 pour le traitement du cancer de la prostate	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer	23/05
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%	23/05
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer	23/05
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug	10/05
Lekna, Inc. Obtains IND Approval from the CDE for LAE102	10/05
Laekna Releases 2023 ESG Report	29/04
Laekna Scores FDA Nod for Obesity Drug LAE102	15/04
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102	15/04
Laekna Shrinks Loss in Fiscal 2023	27/03
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug	11/03
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration	11/03
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities	01/03
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102	29/02
Laekna, Inc. Announces Management Changes	02/02
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34%	29/01
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China	28/01
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer	15/01
Laekna, Inc. Announces Executive Changes	15/01
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024	04/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Laekna, Inc.

Actions

2105

KYG5340S1093

Autres langues

Filtres